SCHEMBL2492414

SCHEMBL2492414

O=C(O)c1cc(NC(=O)C(F)(F)F)ccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.58
KDM4E B2RXH2 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
NPC1 O15118 1/20 0.58
MAPT P10636 1/20 0.58
RAB9A P51151 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
ALDH1A1 P00352 3/20 0.49
TP53 P04637 1/20 0.49
KDR P35968 1/20 0.47
PLA2G1B P04054 1/20 0.47
GAA P10253 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
ACLY P53396 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8278647 0.86 L3MBTL1 (0.58) MAPTL3MBTL1MEN1KMT2ALMNA
SCHEMBL13690000 0.83 L3MBTL1 (0.55) MAPTL3MBTL1MEN1KMT2ALMNA
SCHEMBL4403329 0.83 EPHX1 (0.63) KDM4ENPC1MAPTRAB9AL3MBTL1
SCHEMBL5388065 0.81 TP53 (0.60) MAPTMEN1KMT2ALMNATP53
SCHEMBL478878 0.80 AR (0.56) MAPTL3MBTL1MEN1KMT2ALMNA
SCHEMBL9823940 0.80 MEN1 (0.52) NPC1MAPTRAB9AL3MBTL1MEN1
SCHEMBL29486454 0.80 AR (0.56) MAPTL3MBTL1MEN1KMT2ALMNA
SCHEMBL31619607 0.80 KDM4E (0.66) POLBKDM4ETDP1NPC1MAPT
SCHEMBL2499018 0.80 KDM4E (0.66) POLBKDM4ETDP1NPC1MAPT
SCHEMBL20400826 0.79 ABCC9 (0.52) NPC1MAPTRAB9AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 POLB 2267/4885KDM4E 630/4885TDP1 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.